Phase 1b study of CTP-518 for HIV
Concert Pharmaceuticals announced that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral protease inhibitor for the treatment of HIV infection.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.